Pharmaceutical Research and Development - In 2024, the company achieved significant progress in pharmaceutical research and development, with 4 formulation products receiving market approval and 1 formulation product passing consistency evaluation[4] - Six raw material drug varieties and pharmaceutical excipients received A certification, while five raw material drug varieties obtained international certification[4] - The company launched 4 formulation products and 2 functional skincare products in 2024, enhancing its product matrix in the skin health sector[58] - The company has developed 2 new Class I drugs and over 20 generic drugs, with nearly 30 formulations passing or deemed equivalent for consistency evaluation[86] - The company has established a comprehensive data service platform to support its sales network and marketing strategies[87] - The company is expanding its product pipeline with multiple drug registration applications currently under review, including treatments for pain management and neurological diseases[115] - The company is committed to green and clean production technologies, focusing on reducing the environmental impact of its manufacturing processes[114] Financial Performance - The company's operating revenue for 2024 was CNY 11,664,669,783.79, representing a 0.60% increase compared to CNY 11,594,590,416.29 in 2023[40] - The net profit attributable to shareholders for 2024 was CNY -298,989,917.10, a significant decrease of 198.96% from CNY 302,122,026.53 in 2023[40] - The cash flow from operating activities for 2024 was CNY 1,625,292,850.24, which is a 2.25% increase from CNY 1,589,476,654.26 in 2023[40] - The total assets at the end of 2024 were CNY 29,450,469,334.61, down 4.16% from CNY 30,727,396,560.35 at the end of 2023[40] - The company's basic earnings per share for 2024 was CNY -0.1514, a decline of 199.21% from CNY 0.1526 in 2023[40] - The company reported an operating loss of CNY 12,743.50 million, a decrease of 113.75% year-on-year[98] - The company incurred non-operating losses of CNY 19,593,772.29 from the disposal of non-current assets in 2024[47] Medical Services and Operations - The medical business showed steady growth, with bed occupancy rates exceeding 90% at Beijing Huasheng Rehabilitation Hospital, indicating strong operational performance[10] - The company’s medical services, particularly at Chongqing Songshan Hospital, experienced steady growth in outpatient and surgical volumes, with bed occupancy rates exceeding 90%[59] - The company invested in the Chongqing Songshan Hospital, leading to the establishment of 16 specialized outpatient clinics, enhancing service capabilities[59] - The company aims to develop a high-quality medical service system in response to the aging population and increasing demand for healthcare services in major cities, focusing on comprehensive healthcare, rehabilitation, and cancer treatment[141] Market Expansion and Strategy - The company plans to strengthen its position in the prescription market and actively expand into the retail market to increase market share[3] - The company is actively expanding its overseas raw material drug market while consolidating its position in the prescription market domestically[58] - The company is actively expanding its retail market presence, focusing on county-level and grassroots channels, and enhancing online sales through various platforms[64] - The company aims to enhance its capacity utilization and promote CMO and CDMO projects to create additional revenue streams[137] Agricultural and New Materials Business - The agricultural and new materials businesses experienced a decline due to cyclical industry impacts, while the tourism business remained stable[14] - The agricultural chemical sector faced challenges with intensified market competition and high inventory levels, impacting overall performance[54] - The new materials segment experienced a decline in revenue and profit due to raw material price fluctuations and increased industry competition[59] - The agricultural chemical segment has a stable overseas sales revenue proportion of 49.57% for 2024, with a focus on export sales[69] Governance and Compliance - The company received an "A" rating for information disclosure from the Shenzhen Stock Exchange for the 2023-2024 period[165] - The internal audit department conducts audits on related transactions and major expenses to ensure compliance and protect shareholder rights[165] - The company emphasizes the independence of its operations from the controlling shareholders, maintaining a clear asset ownership structure and full control over its assets[167] - The company has established an independent financial management department, adhering to accounting standards and ensuring no interference from controlling shareholders in financial decisions[169] Research and Development - The company has a strong R&D team and facilities, ensuring a competitive edge in the production of chlorosulfonic acid and other fine chemical products[73] - The company has developed over 100 high-quality products in herbicides, fungicides, and insecticides, with significant market share in the domestic market[91] - The company has established a comprehensive industrial chain from basic chemical raw materials to high-performance polymer materials, positioning itself as a leading producer in its field[73] - The company is focused on developing green production technologies to recycle waste and reduce disposal costs[82] Tourism Business - The company operates three cable cars in the Yulong Snow Mountain Scenic Area and three in the Taibai Mountain National Forest Park, being the sole operator in these scenic areas[77] - The company has hotel operations in regions such as Yunnan, Chongqing, and Guangxi, including several high-end hotels like the InterContinental Resort in Lijiang[78] - The tourism service sector generated revenue of CNY 1,103,451,946.30, accounting for 9.46% of total revenue, with a year-on-year increase of 1.70%[99] Human Resources and Management - The total number of employees at the end of the reporting period was 12,572, with 61 in the parent company and 12,511 in major subsidiaries[193] - The professional composition includes 6,293 production personnel, 1,855 sales personnel, 1,965 technical personnel, 385 financial personnel, 1,614 administrative personnel, and 460 medical personnel[193] - The company has a comprehensive salary system based on "efficiency first, fairness considered, and performance highlighted," incorporating basic salary, performance bonuses, and equity incentives[194] - The training program focuses on talent development, internal collaboration, and resource sharing to enhance employee skills and efficiency[195]

华邦健康（002004）公告，2025年第一季度营业收入28.21亿元，同比下降3.24%。净利润1.84亿元，同 比增长18.50%。 ...

华邦健康（002004）公告，2024年营业收入116.65亿元，同比增长0.60%。归属于上市公司股东的净亏 损2.99亿元，去年同期净利润3.02亿元。基本每股收益-0.1514元/股。公司董事会审议通过的利润分配预 案为不派发现金红利，不送红股，不以资本公积金转增股本。 ...

截至4月11日收盘，转基因概念下跌5.96%，位居概念板块跌幅榜前列，板块内，万向德农跌停，神农 种业、敦煌种业、丰乐种业等跌幅居前，股价上涨的有3只，涨幅居前的有芭田股份、金城医药、科前 生物等，分别上涨5.63%、1.91%、1.07%。 转基因概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002385 | 大北农 | -7.17 | 10.09 | -15703.93 | | 300087 | 荃银高科 | -8.83 | 12.71 | -10991.72 | | 300189 | 神农种业 | -13.04 | 40.95 | -10713.62 | | 000998 | 隆平高科 | -5.46 | 7.89 | -6747.25 | | 002041 | 登海种业 | -6.88 | 6.53 | -5055.55 | | 000713 | 丰乐种业 | -9.02 | 18.03 | -4946.29 | | 600354 | 敦煌种业 | -9.25 | 20. ...

证券代码：002004 证券简称：华邦健康 公告编号：2025008 华邦生命健康股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司实际控制 人张松山先生的通知，获悉其将所持有本公司的部分股份办理解除质押业务，具 体情况如下： 一、本次解除质押基本情况 | 股东 名称 | 是否为控股股东或第一 大股东及其一致行动人 | 本次解除质押 股份数量 （股） | 占其所持股 份比例 | 占公司总股 本比例 | 质押起始日 | 解除质押日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 张松山 | 是 | 32,000,000 | 27.33% | 1.62% | 2024.03.27 | 2025.03.27 | 西南证券 | | | | | | | | | 股份有限公司 | 二、张松山先生及其一致行动人股份累计质押基本情况 截至本公告披露日，张松山先生及其一致行动人西藏汇邦科技有限公司（ ...

1、药品名称：卡泊三醇倍他米松软膏 2、剂型： 软膏剂 证券代码：002004 证券简称：华邦健康 公告编号：2025007 华邦生命健康股份有限公司 关于全资子公司获得《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）全资子公司重庆华邦制药 有限公司（以下简称"华邦制药"）于近日收到国家药品监督管理局核准签发的 关于卡泊三醇倍他米松软膏的《药品注册证书》，现将有关情况公告如下： 一、药品基本情况 3、规格：30g；15g 5、注册分类：化学药品 4 类 6、受理号：CYHS2303654、CYHS2303655 7、药品批准文号：国药准字 H20253639、国药准字 H20253640 8、证书编号：2025S00741、2025S00742 10、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。符合药品生产质量管理规范要求方可生产销售。 二、药品的相关信息 卡泊三醇倍他米松 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025006 华邦生命健康股份有限公司 关于实际控制人部分股份质押的公告 截至本公告披露日，张松山先生及其一致行动人西藏汇邦科技有限公司（以 下简称"汇邦科技"）、张一卓先生、赵丹琳女士所持质押股份情况如下： | | | | | | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 （股） | 持股比 例 | 累计质押数量 （股） | 占其所持 股份比例 | 总股本 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | | | 比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | | | | | | 数量（股） | 比例 | 数量（股） | 比例 | | 汇邦科技 | 370,449,804 | 18.71% | 185,000,000 | 49.94% | 9.34% | 0 | 0.00% | 0 | 0.00% | | 张松山 | 117,095, ...

二、本无异议函不表明本所对债券的投资风险或者收益等作出判断或者保证。 证券代码：002004 证券简称：华邦健康 公告编号：2025005 华邦生命健康股份有限公司 关于收到《关于华邦生命健康股份有限公司非公开 发行科技创新可交换公司债券符合深交所挂牌条件 的无异议函》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）分别于 2024 年 12 月 10 日召开第八届董事会第二十一次会议、2024 年 12 月 26 日召开 2024 年第一次临 时股东大会，审议通过了以本公司所持的山东凯盛新材料股份有限公司（股票代 码：301069）A 股股票非公开发行可交换公司债券的相关议案。具体内容详见公 司于 2024 年 12 月 11 日在《中国证券报》、《证券时报》、《上海证券报》及巨潮 资讯网（www.cninfo.com.cn）刊载的《关于非公开发行可交换公司债券的公告》 （公告编号：2024045）。基于公司实际经营情况，公司董事长、总经理根据股东 大会及董事会的授权对本次非公开发行可交换公司债券方案中的发 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025004 华邦生命健康股份有限公司 关于使用暂时闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：低风险、流动性好、安全性高的短期（不超过一年）理财产 品，包括但不限于商业银行、非银行金融机构发行的低风险型理财产品、结构性 存款产品、固定收益凭证等。 2、投资金额：华邦生命健康股份有限公司（以下简称"公司"）及下属子公 司购买理财产品额度不超过人民币 230,000 万元，在该额度内资金可以滚动使用。 3、特别风险提示：公司及下属子公司使用闲置自有资金进行现金管理所涉 及的产品属于商业银行、非银行金融机构发行的低风险理财产品，但金融市场受 宏观经济的影响较大，不排除该投资受到市场波动的影响。 一、投资情况概述 （一）投资目的 为提高资金使用效率，合理利用闲置资金，在不影响公司正常经营和主营业 务发展的前提下，利用闲置自有资金购买商业银行、非银行金融机构低风险、流 动性好、安全性高的短期（不超过一年）理财产品，增加公司现金资产收益。 （二）投资 ...

华邦生命健康股份有限公司 第八届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第八届董事会第二十二次 会议通知于 2025 年 3 月 3 日以电子邮件的形式发出，2025 年 3 月 6 日通过通讯 表决的方式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符合《公 司法》及《公司章程》的规定，合法有效。会议由董事长张松山先生主持，经与 会各位董事认真讨论研究，审议并通过了如下议案： （一）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于 使用暂时闲置自有资金进行现金管理的议案》。 证券代码：002004 证券简称：华邦健康 公告编号：2025003 详见公司同日在《中国证券报》、《证券时报》、《上海证券报》及巨潮资讯网 （www.cninfo.com.cn）刊载的《关于使用暂时闲置自有资金进行现金管理的公告》 （公告编号：2025004）。 （二）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2025 年度财 ...